Oferlanz (Lisdexamfetamine Diadipate)

Oferlanz is a stimulant that acts on neuro‑behavioral pathways associated with attention and impulse control.

• Attention‑deficit/hyperactivity disorder (ADHD): Improves concentration, reduces hyperactivity and supports better executive functioning.
• Binge‑eating disorder (BED): Decreases the frequency of binge episodes and helps regulate appetite control.
• Narcolepsy (off‑label): May improve daytime wakefulness, though it is not a primary indication.

• Lisdexamfetamine diadipate is a pro‑drug that is enzymatically converted after oral ingestion to d‑amphetamine. The released d‑amphetamine increases synaptic concentrations of norepinephrine and dopamine by promoting their release and blocking reuptake, which enhances cortical signaling involved in attention, impulse control and wakefulness.

Adverse reactions to Oferlanz can range from mild to severe and should be monitored during therapy.

Common Side Effects

• Insomnia
• Decreased appetite
• Dry mouth
• Headache
• Irritability
• Weight loss

Serious or Rare Side Effects

• Cardiovascular events (e.g., hypertension, tachycardia)
• Psychiatric symptoms (e.g., psychosis, mania)
• Severe allergic reactions
• Growth suppression in children
• Peripheral vasculitis
• Seizures

Before prescribing Oferlanz, clinicians should evaluate cardiovascular health, psychiatric history and potential for misuse.

• Cardiovascular assessment: Obtain baseline blood pressure and heart rate.
• Psychiatric screening: Review history of psychosis, bipolar disorder or severe anxiety.
• Substance‑use evaluation: Assess risk of abuse or diversion.
• Growth monitoring: Track height and weight in pediatric patients.
• Drug‑interaction review: Check concomitant medications that affect catecholamine pathways.
• Store at ambient temperature: keep in original container, protect from moisture and light.

Oferlanz may interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Mono‑Mono‑Mono  :            ...

Moderate  …